BioSpace News Archive

Lineage Cell Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”.

IMIDomics Inc. today announced a strategic license and collaboration agreement with the University of Barcelona (UB).

Nucleix today announced recent updates in its lung cancer detection program for early-stage disease.

Ferring Pharmaceuticals today announced four poster presentations at Infectious Disease Week (IDWeek) 2023 for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

SELLAS Life Sciences Group, Inc. today announced that its partner GenFleet Therapeutics (Shanghai), Inc. has dosed the first patient in a Phase Ib/II trial evaluating SLS009 (GFH009) in relapsed/refractory Peripheral T-cell Lymphomas (PTCL).

CorMedix Inc. today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15.

NurExone Biologic Inc. is thrilled to announce that the Company has been awarded a 1M New Israeli Shekels (NIS) (~CAD$350K) grant by the Israel Innovation Authority (“ IIA ”) as part of the Israel-Canada bilateral Eureka program.

AbbVie (NYSE: ABBV) today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.

Alopexx, Inc. is scheduled to present pre-clinical data at IDWeek 2023’s Microbial Pathogenesis of Alzheimer’s Disease symposium being held October 11-15, 2023 in Boston, MA.

CSL Seqirus, a business of CSL, announced new data from three studies supporting the clinical, public health and economic value of both cell-based and adjuvanted seasonal influenza vaccines.